Dinalbuphine sebacate
Opioid analgesic chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Dinalbuphine sebacate?
Summarize this article for a 10 year old
Dinalbuphine sebacate (DNS), also known as nalbuphine sebacate or as sebacoyl dinalbuphine ester (SDE) and sold under the brand name Naldebain, is a non-controlled opioid analgesic which is used as a 7-day long-acting injection in the treatment of moderate to severe postoperative pain.[3][4][5]
Clinical data | |
---|---|
Other names | DNS; Nalbuphine sebacate; Sebacoyldinalbuphine; SDN; Sebacoyl dinalbuphine ester; SDE; LT-1001 |
Routes of administration | Intramuscular injection |
Drug class | Opioid analgesic |
Pharmacokinetic data | |
Bioavailability | • IMTooltip Intramuscular injection: 85.4% (relative to nalbuphine)[1] |
Metabolism | Hydrolysis[2] |
Metabolites | Nalbuphine[1] |
Elimination half-life | • DNS: 83.2 hours (mean absorption time: 145.2 hours)[1] • Nalbuphine: 4.0 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C52H68N2O10 |
Molar mass | 881.120 g·mol−1 |
3D model (JSmol) | |
| |
|
The compound is a diester of nalbuphine (Nubain) joined via a sebacic acid linker, and acts as a long-lasting prodrug of nalbuphine via slow hydrolysis.[5][2][6] It was developed to extend the duration of action of nalbuphine, which has a short duration and requires frequent injections.[7][5][2][1] Whereas nalbuphine must be injected every 4 to 6 hours, a single injection of DNS lasts for up to 7 to 10 days.[5]
It was invented by professor Oliver Yoa-Pu Hu (National Defense Medical Center) and codeveloped with Lumosa Therapeutics. Naldebain received market approvals from Taiwan FDA in March 2017, Health Sciences Authority of Singapore in December 2020, the Ministry of Public Health of Thailand in December 2021, the Drug Control Authority of Malaysia in 2022, State Service of Ukraine on Medicines and Drugs Control and Brunei Darussalam Medicines Control Authority (BDMCA) in 2023.[3][4] Development is ongoing in the United States, China, Korea, and the Philippines.[8]